



European Cystic Fibrosis Society (ECFS) 2023

Vienna, Austria

Friday 9 June 2023 | 12:30–14:00 CEST | Austria Center, Hall E

A journey of innovation: What's next for people with CF?

This symposium is organised and entirely funded by Vertex Pharmaceuticals (Europe) Limited.

This symposium is for healthcare professionals only, it is not open to patients or members of the public.

Learning objectives

This symposium aims to:

- Highlight the challenges and opportunities for measuring treatment efficacy in the era of CFTR modulators, and the need for more sensitive measures of treatment efficacy
- Explore the value and limitations of key biomarkers currently being used to measure CFTR function in clinical trials and in the real world
- Highlight progress to date and future direction for developing innovative therapies for all people with CF (pwCF)

Agenda

Time (CEST)	Topic	Speaker
12:30–12:40	Chair's intro: Where are we now?	Prof. Isabelle Fajac University of Paris, France
12:40–12:55	Measuring clinical outcomes in CF: Challenges and opportunities	Prof. Jane Davies National Heart and Lung Institute, UK
12:55–13:10	CFTR function from diagnosis to outcomes: A look forward	Dr Patrick Sosnay Vertex Pharmaceuticals, USA
13.10–13:25	Continuing the journey of innovation in CF	Dr Fred van Goor Vertex Pharmaceuticals, USA
13:25–13:55	Q&A and discussion	All speakers
13:55–14:00	Chair's close	Prof. Isabelle Fajac University of Paris, France